Treatment of hyperproliferative disease with superantigens in combination with another anticancer agent

US8293243B2 · kind B2 · utility

Assignee

• Active Biotech AB · SE

Inventors

• Gunnar Hedlund · Lund, SE
• Goran Forsberg · Karlstad, SE
• Marie Wallén-öhman · Lund, SE

Key dates

• Filing date: May 25, 2010
• Grant date: Oct 23, 2012
• Expiry date: Feb 22, 2031

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/33
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to methods of treating mammals affected by, for example, a hyperproliferative disease such as cancer, by administering a tumor-targeted superantigen and a chemotherapeutic agent, whereby the administration of the tumor-targeted superantigen and chemotherapeutic agent reduce the antibody response and enhance the T cell response. The superantigen, wild-type or modified, is fused to a target-seeking moiety, such as an antibody or an antibody active fragment. The combined administration of a superantigen and a chemotherapeutic agent provides enhanced therapeutic effects in a treated animal.